Gliatilin, 400 mg capsules 56 pcs

Indications

Cerebral circulation disorders of ischemic type (acute and recovery periods) and hemorrhagic type (recovery period).
Psychoorganic syndrome against the background of involutional and degenerative processes of the brain.
Consequences of cerebrovascular insufficiency or primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration.
Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest; senile pseudomelancholia.
Multi-infarct dementia.

Pharmacological effect

PHARMACOTHERAPEUTIC GROUP: nootropic agent

ATX code: N07AX02

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Gliatilin is a choline alfoscerate, which is a centrally acting cholinomimetic with a predominant effect on the central nervous system.

The drug contains 40.5% choline, released from a compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nervous excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on the transmission of nerve impulses, and glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), resulting in improved membrane elasticity and receptor function.

Gliatilin enhances metabolic processes and activates the structures of the reticular formation of the brain.

It has a preventive and corrective effect on the factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Pharmacodynamic studies have shown that Gliatilin acts on synaptic, including cholinergic transmission of nerve impulses (neurotransmission), neuronal membrane plasticity and receptor function.

Pharmacokinetics

Absorption when taken orally – 88%; easily penetrates the blood-brain barrier, accumulates mainly in the brain (concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Does not affect the reproductive cycle, does not have teratogenic or mutagenic effects.

Special instructions

Nausea may result from dopaminergic activation.

Efficacy and safety in children under 18 years of age have not been established.

INFLUENCE ON THE ABILITY TO MANAGE TRANSPORT

MEANS AND MECHANISMS

During the treatment period, care must be taken when driving vehicles and when engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Choline alphoscerate

Composition

One capsule contains:

Active ingredient: choline alfoscerate 400.0 mg.

Excipients: glycerol, purified water. Composition of the capsule shell: gelatin, esitol, sorbitans,

sodium ethyl parahydroxybenzoate, sodium propyl parahydroxybenzoate, titanium dioxide (E171), iron oxide dye (E172).

Pregnancy

The use of Gliatilin during pregnancy and breastfeeding is contraindicated.

Contraindications

Hypersensitivity to the components of the drug.
Pregnancy.
Breastfeeding period.
Children under 18 years of age (due to lack of data).

Side Effects

From the digestive system: nausea (which is mainly a consequence of secondary dopaminergic activation), abdominal pain. From the nervous system: short-term confusion (in this case it is necessary to reduce the dose of the drug).
The drug is well tolerated even with long-term use.

Interaction

Clinically significant interactions of the drug with other drugs have not been established.

Overdose

Symptoms: nausea.
The severity of dose-dependent side effects may increase.
Treatment: symptomatic therapy. The effectiveness of dialysis has not been established.

Storage conditions

At a temperature not higher than 25°C.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Catalent Italy S.P.A., Italy